Elucidating the specific pharmacological system of action (MOA) of naturally developing compounds may be challenging. Whilst Tarselli et al. (60) produced the first de novo synthetic pathway to conolidine and showcased this naturally occurring compound correctly suppresses responses to equally chemically induced and inflammation-derived pain, the pharmacologic target accountable https://www.proleviate.com/post/conolidine-an-alternative-natural-pain-relief-to-replace-traditional-painkillers